| Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) C Pinto, F Di Fabio, S Siena, S Cascinu, FLR Llimpe, C Ceccarelli, V Mutri, ... Annals of Oncology 18 (3), 510-517, 2007 | 411 | 2007 |
| Real-world study of everolimus in advanced progressive neuroendocrine tumors F Panzuto, M Rinzivillo, N Fazio, F de Braud, G Luppi, MC Zatelli, F Lugli, ... The oncologist 19 (9), 966-974, 2014 | 109 | 2014 |
| The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab FD Fabio, C Pinto, FL Rojas Llimpe, S Fanti, P Castellucci, C Longobardi, ... Gastric Cancer 10, 221-227, 2007 | 74 | 2007 |
| Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer A Sartore-Bianchi, K Bencardino, A Cassingena, F Venturini, C Funaioli, ... Cancer treatment reviews 36, S1-S5, 2010 | 46 | 2010 |
| Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III … R Ricotta, A Verrioli, S Ghezzi, L Porcu, A Grothey, A Falcone, ... ESMO open 1 (6), e000111, 2016 | 35 | 2016 |
| Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic … A Sartore-Bianchi, K Bencardino, F Di Nicolantonio, F Pozzi, C Funaioli, ... Targeted oncology 5, 19-28, 2010 | 35 | 2010 |
| Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic … A Sartore-Bianchi, K Bencardino, F Di Nicolantonio, F Pozzi, C Funaioli, ... Targeted oncology 5, 19-28, 2010 | 35 | 2010 |
| The impact of chemotherapy on overall survival and quality of life of patients with metastatic colorectal cancer: a review of phase III trials C Funaioli, C Longobardi, AA Martoni Journal of chemotherapy 20 (1), 14-27, 2008 | 29 | 2008 |
| Does biomolecular characterization of stage II/III colorectal cancer have any prognostic value? C Funaioli, C Pinto, V Mutri, F Di Fabio, C Ceccarelli, AA Martoni Clinical colorectal cancer 6 (1), 38-45, 2006 | 19 | 2006 |
| Pooled analysis of clinical outcome of patients with chemorefractory metastatic colorectal cancer treated within phase I/II clinical studies based on individual biomarkers of … A Sartore-Bianchi, A Amatu, E Bonazzina, S Stabile, L Giannetta, G Cerea, ... Targeted Oncology 12, 525-533, 2017 | 16 | 2017 |
| 18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy C Funaioli, C Pinto, F Di Fabio, D Santini, C Ceccarelli, E De Raffaele, ... Tumori Journal 93 (6), 611-615, 2007 | 16 | 2007 |
| 18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy C Funaioli, C Pinto, F Di Fabio, D Santini, C Ceccarelli, E De Raffaele, ... Tumori Journal 93 (6), 611-615, 2007 | 16 | 2007 |
| Real-world study of everolimus in advanced progressive neuroendocrine tumors F Panzuto, M Rinzivillo, N Fazio, F de Braud, G Luppi, MC Zatelli, F Lugli, ... The Oncologist 20 (5), 570-570, 2015 | 13 | 2015 |
| Predictive value of circulating VEGF in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma treated with cetuximab in combination with cisplatin … F Di Fabio, C Pinto, E Bucca, S Giaquinta, AS Fabricio, V Mutri, S Michilin, ... Journal of Clinical Oncology 26 (15_suppl), 15605-15605, 2008 | 7 | 2008 |
| Prognostic significance of ki67, p53, TS and EGFR in advanced gastric and gastroesophageal junction cancer patients treated with cetuximab plus FOLFIRI (FOLCETUX study) FL Rojas Llimpe, F Di Fabio, C Ceccarelli, C Pinto, S Siena, S Cascinu, ... Journal of Clinical Oncology 25 (18_suppl), 4604-4604, 2007 | 6 | 2007 |
| Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab+ irinotecan as predictive factor of efficacy and outcome B Vincenzi, D Santini, C Funaioli, C Pinto, F Di Fabio, S Galluzzo, ... Journal of Clinical Oncology 26 (15_suppl), 4106-4106, 2008 | 3 | 2008 |
| Evaluation of electrolytic imbalance in patients with advanced colorectal and gastric cancer treated with anti-EGFR monoclonal antibody-based therapy C Funaioli, C Pinto, F Di Fabio, N Malavasi, P Di Tullio, S Pini, B Vincenzi, ... Journal of Clinical Oncology 26 (15_suppl), 14631-14631, 2008 | 2 | 2008 |
| Neuroimaging abnormalities in adult medulloblastoma undergoing intensified therapy S Secondino, A Citterio, P Pedrazzoli, C Funaioli, GG Scialfa, S Siena Anticancer research 28 (6B), 3991-3992, 2008 | 1 | 2008 |
| 18FDG-PET in targeted therapy with cetuximab in gastric or gastroesophageal junction (GEJ) adenocarcinoma: First results of the Italian FOLCETUX Study F Di Fabio, C Pinto, S Fanti, FL Rojas Llimpe, C Longobardi, C Nanni, ... Journal of Clinical Oncology 24 (18_suppl), 4061-4061, 2006 | 1 | 2006 |
| An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study V Internò, F Massari, R Rudà, BA Maiorano, O Caffo, G Procopio, ... ESMO open 8 (4), 101598, 2023 | | 2023 |
